C. Randall Harrell, M.D.
Our Founder, Chairman, CEO and Chief Medical Officer, Dr. Harrell has had a long term interest in Regenerative Medicine . This new branch of medicine will develop New Human Derived Biomaterials that will replace and regenerate aging organ and tissue systems. This will follow the old Plastic Surgery wisdom of "replacing like with like." Dr. Harrell is also the inventor of Humallagen® and is responsible for obtaining its patents. As a practicing plastic surgeon he has been at the forefront of plastic surgery since 1989.
Dr. Harrell owns and operates The Fountain of Youth Institute, a plastic surgery practice in Palm Harbor, FL. Dr. Harrell has authored numerous papers in medical journals and is often invited as a speaker at conferences and seminars and as a commentator for TV, radio and print media. Dr. Harrell received his training from Baylor College of Medicine at Texas Medical Center, Houston,Texas-The largest Medical Center in the World and is also trained in cardiac surgery with Dr. Michael DeBakey. Dr. Harrell was nominated for the Nobel Peace Prize for his charity work in Central America.
Jean-Louis Tayot, PhD
Chief Science Officer Consultant, Member of Science Advisory Board. Dr. Tayot is responsible for the collagen manufacturing process and technologies. Dr. Tayot is CEO of Khorionyx, a French Human Biomaterial Company. He retired December 2005 as the Chief Scientific Officer of Floreane Medical Implants, a leading French medical device company, and General Manager of its subsidiary Imedex Biomatériaux. Dr. Tayot has 20 years of R&D experience dedicated to collagen and to the extraction and commercialization of valuable biomaterials from human placentas. Through Imedex, he spent $20 million and 15 years developing and refining the collagen manufacturing process technology that is now exclusively available to Albiorex. Dr. Tayot holds numerous medical device patents related to the production, manipulation and use of collagen in numerous medical applications and has successfully launched products in the U.S. and other regulatory environments. He also led Aventis-Pasteur’s R&D and enzyme production operations where he eventually sourced and processed 20 tons of human placentas per day.
Richard T. Welch
Richard T. Welch - Mr. Welch is a Certified Public Accountant (Louisiana Inactive) and graduated from Louisiana State University in 1973 with a Bachelor of Science in Industrial Management followed by Accounting in 1977. Mr. Welch is also a Series 79 Registered Investment Banker currently unaffiliated. Mr. Welch has managed or advised on all aspects including valuations, deal structure, and negotiations of 50 plus completed M&A transactions aggregating over $ 1 billion in enterprise value, and over $ 1 billion in funded capital transactions covering the spectrum of the capital structure. Over his career Rick has also served as an advisor for strategic, capital structure, and business development matters for startup and large private companies; as a director, chairman of board, chair of special committees, and chair of the audit committee of publicly traded companies; and in different operations and management roles for private companies.
Crissy Fellabaum, PhD
Dr. Fellabaum comes to RPP with over 25 years of engineering, operations management, and quality assurance experience in the insurance and medical industries, working closely with multiple governmental regulatory agencies. She has also served as a corporate trainer and quality control manager and as a licensed Neuromuscular Therapist, having worked with various sports agencies. Dr. Fellabaum has her PhD in Biomedical Engineering, a Double Master’s Degree in Sports Medicine and Biomedical Engineering and a Bachelors Degree in Chemical Engineering. She comes from a strong military family with her son currently serving in the Army and her father a retired Marine. She also has a daughter in college working towards her medical degree.
Eric W. Wilkinson
Eric W. Wilkinson - Eric comes to RPP with over 30 years experience in biotechnology and medical devices working his way from Scientist to Senior Executive.
Mr. Wilkinson has founded or co-founded 6 biotech companies which have included successful IPO’s and other financing transactions. He has served as Chief Executive Officer, President, or Vice President of companies including Synthetic Genetics, DNA Sciences, Genetic Vectors, XL TechGroup, DxTech, and Phoenix Molecular. He has served on a number of Boards of Directors of both public and private companies.
Mr. Wilkinson’s previous R&D positions include IDEC Pharmaceuticals, Cleveland Clinic Foundation, and the Norwegian Institute of Public Health.
Marissa Morris, PhD
A former news anchor for major network affiliates, our spokesperson, press representative and media (video, still and audio) producer.
Randy Wagner is an experienced business executive, and classically trained scientist, having served almost 30 years in life sciences research and development. He began his academic career studying the effects of novel human biological response modifiers (i.e. interferons, interleukins, and monoclonal antibodies) at the University of Wisconsin’s, NCI designated, Comprehensive Cancer Center. That preclinical experience and the successes around developing and directing core support operations, advanced his technical understandings and compelled him to move forward and start his first biotechnology company, ProtoPROBE, Incorporated.
Randy served as the founder and CEO of ProtoPROBE, Inc. for 10 years. During those years he served the custom bio-tool and diagnostic assay development needs of some of the most prominent biotechnology and academic research institutions. His work has been sited in prestigious scientific journals and company trade publications. He has proven technical expertise and proficiencies in many areas of cellular immunology and molecular biology research and development, and all aspects of bio-assay development, from concept through finished assay.
Some of his more noteworthy scientific accomplishments include the development of patented monoclonal antibody based quantitative assays, that measure proteins in complex mixtures in both their native and denatured forms, and assays that specifically characterize novel conformational events (i.e. vitamin and small molecule interactions with their binding domains, protein to protein, and protein to receptor complexes).
Over his 30 year career in biomedical research and biotechnology Randy has served as a research scientist, Director of Core Research Facilities, Director of Product Development, Biotechnology Technical Consultant, Immunodiagnostic Assay Development, Manager of Quality Assurance
Interesting linksHere are some interesting links for you! Enjoy your stay :)
Browse Our Site
Regenerative Processing Plant, LLC
Fountain of Youth Building
34176 US Highway 19 N
Palm Harbor, FL 34684
Phone: (800) 781-0818 ((800) 781-0818)
Fax: (727) 787-7512